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Abstract
Introduction The objective of this study was to assess the
impact of certolizumab pegol (CZP) treatment on health-related
quality of life (HRQoL), fatigue and other patient-reported
outcomes (PROs) in patients with rheumatoid arthritis (RA).
Methods Patients with active RA (N = 982) were randomized
2:2:1 to subcutaneous CZP (400 mg at weeks 0, 2 and 4;
followed by CZP 200 mg or 400 mg) plus methotrexate (MTX)
every other week, or placebo (PBO) plus MTX. PRO
assessments included HRQoL, fatigue, physical function,
arthritis pain and disease activity. Adjusted mean changes from
baseline in all PROs were obtained using analysis of covariance
(ANCOVA) applying last observation carried forward (LOCF)
imputation. The proportion of patients achieving clinically
meaningful improvements in each PRO was obtained using
logistic regression and by applying non-responder imputation to
missing values after rescue medication or withdrawal. The
correlations between PRO responses and clinical responses
were also assessed by tetrachoric correlation using non-
responder imputation.
Results Patients treated with CZP plus MTX reported
significant (P < 0.001), clinically meaningful improvements in
HRQoL at the first assessment (week 12); reductions in fatigue,
disease activity and pain and improvements in physical function
were reported at week 1. In particular, CZP-treated patients
reported improvements in mental health. Mean changes from
baseline in the SF-36 Mental Component Summary (MCS) at
week 52 for CZP 200 mg and 400 mg plus MTX, and PBO plus
MTX were 6.4, 6.4 and 2.1, respectively (P < 0.001). In addition,
mental health and vitality scores in CZP-treated patients
approached age- and gender-adjusted US population norms.
Improvements in all PROs were sustained. Similar benefits were
reported with both CZP doses. Changes in SF-36 MCS scores
ANCOVA: analysis of covariance; CZP: certolizumab pegol; DAS: disease activity score; DMARD: disease modifying antirheumatic drug; FAS: fatigue 
assessment scale; HAQ-DI: health assessment questionnaire - disability index; HRQoL: health-related quality of life; ITT: intent to treat; LOCF: last 
observation carried forward; MCID: minimal clinically important difference; MCS: mental component summary; MTX: methotrexate; NRS: numeric rat-
ing scale; PBO: placebo; PCS: physical component summary; PRO: patient-reported outcomes; PtGA: patient's global assessment of disease activ-
ity; RA: rheumatoid arthritis; RAPID 1: RA PreventIon of Structural Damage 1; SF-36: short-form 36-item health survey; TNF: tumor necrosis factor; 
VAS: visual analog scale.Arthritis Research & Therapy    Vol 11 No 6    Strand et al.
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had the lowest correlation with disease activity scores (DAS28)
and American College of Rheumatology 20% improvement
(ACR20) response rates, while improvements in pain showed
the highest correlation.
Conclusions Treatment with CZP plus MTX resulted in rapid
and sustained improvements in all PROs, indicating that the
benefits of CZP extend beyond clinical efficacy endpoints into
areas that are more relevant and meaningful for patients on a
daily basis.
Trial Registration ClinicalTrials.gov NCT00152386.
Introduction
Rheumatoid arthritis (RA) is a common severe inflammatory
disorder characterized by progressive joint damage and func-
tional impairments [1]. It has been widely reported that the
daily-life burdens associated with RA, including functional
impairment, chronic and debilitating pain, inability to partici-
pate in desired family, social and leisure activities and reduced
productivity at work and within the home, have a profound
impact on an individual's health-related quality of life (HRQoL)
[2-5]. As such, HRQoL is now considered to be an essential
outcome measure in many clinical studies [6] and the Ameri-
can College of Rheumatology (ACR), the European League
Against Rheumatism (EULAR) and the Outcomes Measures in
Rheumatology (OMERACT) have recognized the importance
of measuring functioning and well-being from the patient's per-
spective in clinical trials [7].
Another multidimensional burden experienced by almost all
RA patients is fatigue. RA-related fatigue has been reported to
be more extreme than normal tiredness, to restrict patients'
abilities to fulfill their normal family roles and to take a severe
emotional toll on patients [8]. Furthermore, an examination of
both the physical and mental components of fatigue revealed
that high levels of mental fatigue coincide with elevated levels
of bodily pain and physical limitations in patients with RA [9].
Assessing patient's burden is an important component in mon-
itoring both the progression of disease and the effectiveness
of RA therapies. Physician-reported measures offer the physi-
cian's assessment of patient's health, while patient-reported
assessments of both the physical (fatigue and pain) and men-
tal burden of RA reflect the impact of disease on everyday life.
Moreover, some of these symptoms (especially those that are
mental/emotional in nature) are known only to, and can thus
only be reported by, patients. An analysis of randomized con-
trolled trials has shown that patient-reported outcomes dem-
onstrate better discrimination of the treatment effect than more
traditional physician-reported outcomes [10,11], and are,
therefore, the most sensitive tools for assessing the impact of
therapy on RA symptoms [12]. Taken together, the patient and
physician-reported assessments are complementary and pro-
vide a holistic picture of a patient's disease state or well-being.
The efficacy and safety of certolizumab pegol (CZP), the only
PEGylated anti-TNF for the treatment of RA, has been estab-
lished in several phase III clinical trials [13-15]. Previously-
reported clinical results from the RA PreventIon of Structural
Damage 1 (RAPID 1) clinical trial have demonstrated that
CZP, dosed at 200 mg or 400 mg every other week plus meth-
otrexate (MTX), provides rapid reductions in the signs and
symptoms of active RA (as assessed by ACR responder rates)
and improvements in disease activity (as assessed by disease
activity scores [DAS28]) in MTX inadequate responders [15].
In this paper, we present the patient-reported outcome (PRO)
results from the RAPID 1 trial, including HRQoL, fatigue, phys-
ical function, pain and patient's global assessment of disease
activity. To further explore the relation between the patient-
reported and clinical (physician-reported) assessments, we
also examined the correlations between the PROs and the
ACR20 and DAS responses.
Materials and methods
Patients
Full details regarding patient inclusion and exclusion criteria
and randomization for RAPID 1 were previously published
[15]. In brief, patients were aged 18 years or older with active
RA (according to the 1987 ACR RA classification criteria
[16]) with an inadequate response to MTX therapy (≥ 10 mg
weekly for ≥ 6 months with stable doses for ≥ 2 months prior
to baseline). Patients were ineligible if they had previously
failed to respond to treatment with a TNF inhibitor. All patients
provided written informed consent.
Study design
RAPID 1 was a phase III, double-blind, randomized, placebo
(PBO)-controlled, multicenter trial in which patients with active
RA were randomized 2:2:1 to receive subcutaneous CZP
(400 mg weeks 0, 2 and 4 followed by CZP 200 mg or 400
mg) plus MTX every other week, or PBO plus MTX. Patients
not achieving ACR20 responses at weeks 12 and 14 were to
be withdrawn from treatment per protocol at week 16. These
patients, and those who completed RAPID 1, were eligible to
enter an ongoing open-label extension study of CZP 400 mg
plus MTX every other week. The study (NCT00152386) was
conducted in accordance with the International Conference
on Harmonisation E6 Note for Guidance on Good Clinical
Practice (CPMP/ICH/135/95) and Declaration of Helsinki. All
elements of the CONSORT checklist for reporting randomized
clinical trials have been previously published in the primary
RAPID 1 publication [15]. Institutional review boards or ethics
committees approved the protocol at each center, and all
patients provided written consent.Available online http://arthritis-research.com/content/11/6/R170
Page 3 of 12
(page number not for citation purposes)
Table 1
Baseline disease activity and PRO scores (ITT population)
Characteristic, mean (SD) CZP 200 mg + MTX
(n = 393)
CZP 400 mg + MTX
(n = 390)
PBO + MTX
(n = 199)
DAS28, range 0-10 6.9 (0.8) 6.9 (0.8) 7.0 (0.9)
PtGA VAS, range 0-100 mm 63.1 (20.3) 64.1 (18.3) 64.2 (19.6)
Pain VAS, range 0-100 mm 62.1 (20.0) 63.8 (17.2) 63.6 (19.9)
HAQ-DI, range 0-3 1.7 (0.6) 1.7 (0.6) 1.7 (0.6)
Fatigue NRS, range 0-10 6.4 (2.0) 6.5 (1.9) 6.7 (2.0)
SF-36
PCS, range 0-100* 30.9 (6.5) 30.8 (6.8) 30.5 (5.8)
MCS, range 0-100* 40.0 (11.2) 39.3 (11.1) 38.6 (11.4)
Domains, range 0-100
Physical Functioning 33.4 (21.4) 32.9 (21.2) 32.0 (20.1)
Role Physical 13.3 (23.7) 12.9 (25.4) 11.2 (20.8)
Bodily Pain 30.6 (15.3) 28.9 (15.9) 28.5 (14.7)
General Health 35.3 (16.5) 35.9 (17.5) 34.9 (15.6)
Vitality 35.8 (18.0) 36.1 (18.6) 32.9 (17.4)
Social Functioning 50.9 (23.8) 48.1 (24.0) 46.6 (25.2)
Role Emotional 32.4 (39.1) 28.9 (38.1) 30.9 (38.7)
Mental Health 53.8 (20.1) 53.5 (20.7) 52.2 (21.2)
* mean US population normative value equals 50
CZP = certolizumab pegol; DAS28 = disease activity score; HAQ-DI = health assessment questionnaire-disability index; ITT = intent to treat; 
MCS = mental component summary; MTX = methotrexate; NRS = numeric rating scale; PBO = placebo; PCS = physical component summary; 
PRO = patient-reported outcomes; PtGA = patient's global assessment of disease activity; SD = standard deviation; SF-36 = short-form 36-item 
health survey; VAS = visual analog scale.
Figure 1
Adjusted mean change from baseline in SF-36 PCS (a) and MCS (b) scores over 52 weeks (ITT population, LOCF) Adjusted mean change from baseline in SF-36 PCS (a) and MCS (b) scores over 52 weeks (ITT population, LOCF). *P < 0.001 for CZP vs PBO by 
ANCOVA (LOCF imputation). ANCOVA = analysis of covariance; CZP = certolizumab pegol; ITT = intent to treat; LOCF = last observation carried 
forward; MCID = minimal clinically important difference; MCS = mental component summary; MTX = methotrexate; PBO = placebo; PCS = physical 
component summary; SF-36 = short-form 36-item health survey.
Patient-reported outcomes
All patient-reported outcomes assessed in the RAPID 1 trial
were secondary endpoints. These PROs included evaluations
of concepts such as HRQoL, fatigue and the patient-reported
components of the ACR core set criteria (physical function,
arthritis pain and patient's global assessment of disease activ-
ity). The PRO instruments assessed in RAPID 1 have been
shown to provide valid and reliable data in prior RA research.
They were properly implemented in the CZP trials in terms of
patient and investigator training, timing of assessments, lin-
guistic validations, and pre-specification of analysis in the sta-
tistical analysis plan. Psychometric properties of the data
based on the endpoints of the patient-reported outcomes areArthritis Research & Therapy    Vol 11 No 6    Strand et al.
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Table 2
Improvements in health-related quality of life at weeks 12, 24 and 52 (ITT population, LOCF)*
Week 12 Week 24 Week 52
CZP 200 
mg
+ MTX
(n = 393)
CZP 400 
mg
+ MTX
(n = 390)
PBO
+ MTX
(n = 199)
CZP 200 
mg
+ MTX
(n = 393)
CZP 400 
mg
+ MTX
(n = 390)
PBO
+ MTX
(n = 199)
CZP 200 
mg
+ MTX
(n = 393)
CZP 400 
mg
+ MTX
(n = 390)
PBO
+ MTX
(n = 199)
PCS
Mean 
score 
(SD)
36.1 (8.9) 36.8 (8.4) 30.7 (7.1) 37.8 (9.5) 38.4 (8.8) 31.4 (7.3) 38.1 (9.5) 38.9 (8.9) 31.5 (7.4)
Mean 
change 
from BL
5.8 (0.5)† 6.4 (0.6)† 0.7 (0.6) 7.7 (0.4)† 8.3 (0.4)† 1.8 (0.6) 7.8 (0.4)† 8.6 (0.4)† 1.7 (0.6)
% MCID 38.2† 36.5† 21.4 46.6† 51.7† 10.9 42.2† 46.1† 11.5
MCS
Mean 
score 
(SD)
45.5 (11.5) 45.7 (11.6) 41.4 (10.8) 45.6 (11.5) 45.6 (11.6) 41.3 (10.7) 45.8 (11.4) 45.4 (11.5) 41.1 (10.8)
Mean 
change 
from BL
5.6 (0.7)† 5.5 (0.7)† 2.0 (0.8) 6.3 (0.6)† 6.5 (0.6)† 2.3 (0.8) 6.4 (0.6)† 6.4 (0.6)† 2.1 (0.8)
% MCID 36.0‡ 33.3 28.1 41.1† 41.9† 13.0 39.2† 38.1† 9.9
Physical 
Functioning
Mean 
score 
(SD)
45.1 (25.8) 46.1 (24.6) 31.2 (21.0) 47.6 (26.5) 48.8 (24.7) 33.3 (22.2) 49.3 (26.9) 50.3 (24.9) 33.1 (22.3)
Mean 
change 
from BL
11.4 (1.4)† 12.2 (1.4)† -1.0 (1.7) 15.6 (1.2)† 16.5 (1.2)† 1.9 (1.6) 16.7 (1.2)† 17.9 (1.2)† 1.7 (1.6)
% MCID 32.1† 33.6† 18.4 42.0† 46.6† 10.7 38.0† 44.3† 9.7
Role Physical
Mean 
score 
(SD)
34.1 (38.3) 33.9 (38.5) 15.0 (28.0) 37.2 (40.4) 38.6 (40.2) 18.0 (30.2) 37.7 (40.3) 39.2 (41.8) 17.3 (30.2)
Mean 
change 
from BL
24.8 (2.4)† 24.2 (2.5)† 6.4 (2.9) 27.8 (2.0)† 29.1 (2.0)† 9.4 (2.8) 26.9 (2.1)† 29.1 (2.0)† 8.1 (2.9)
% MCID 24.9† 24.5‡ 13.9 33.0† 36.8† 10.3 32.2† 31.1† 8.2
Bodily Pain
Mean 
score 
(SD)
47.8 (20.1) 49.6 (20.4) 33.1 (18.5) 51.4 (22.3) 53.4 (20.8) 33.2 (19.4) 52.0 (22.8) 53.9 (22.2) 34.0 (20.1)
Mean 
change 
from BL
18.0 (1.3)† 20.2 (1.4)† 4.5 (1.6) 23.3 (1.1)† 25.8 (1.1)† 6.3 (1.5) 23.5 (1.1)† 26.2 (1.1)† 6.8 (1.6)
% MCID 45.9‡ 43.3‡ 33.3 52.5† 58.2† 15.9 48.8† 50.7† 14.9
General 
Health
Mean 
score 
(SD)
44.0 (18.9) 48.4 (19.6) 36.9 (18.0) 47.4 (19.6) 48.5 (19.7) 37.2 (17.1) 47.5 (20.3) 47.6 (19.2) 36.9 (16.6)Available online http://arthritis-research.com/content/11/6/R170
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consistent with prior evidence of the measurement properties
for each instrument.
HRQoL was assessed using the Short-Form 36-Items (SF-36)
health survey (Version 1.0 standard recall), which is a widely
used generic HRQoL instrument with numerous studies doc-
umenting its validity and reliability as an accurate measure of
generic health concepts in RA [4,10,17-21]. SF-36 assesses
eight domains: Physical Functioning, Role Physical, Bodily
Pain, General Health, Vitality, Social Functioning, Role Emo-
tional and Mental Health, scored from 0 to 100, with higher
scores indicating better HRQoL [22]. The Physical Compo-
nent Summary (PCS) and the Mental Component Summary
(MCS) scores were obtained from normalized and z-trans-
formed domain scores, with normative values of 50 and stand-
ard deviations of 10. Minimum clinically important differences
Mean 
change 
from BL
8.9 (1.1)† 11.1 (1.1)† 2.4 (1.3) 13.2 (0.9)† 14.0 (0.9)† 3.7 (1.2) 13.0 (0.9)† 13.0 (0.9)† 3.1 (1.3)
% MCID 31.1 32.7‡ 24.2 44.3† 45.7† 11.3 40.3† 40.6† 10.3
Vitality
Mean 
score 
(SD)
48.2 (21.4) 50.0 (21.3) 37.0 (19.1) 50.9 (21.6) 51.4 (21.3) 38.3 (19.9) 50.7 (21.7) 51.1 (20.9) 38.4 (20.0)
Mean 
change 
from BL
12.9 (1.3)† 14.4 (1.4)† 2.8 (1.6) 15.5 (1.1)† 16.2 (1.1)† 4.7 (1.5) 15.1 (1.0)† 15.6 (1.0)† 4.5 (1.5)
% MCID 35.5‡ 35.3‡ 27.0 45.1† 45.7† 12.2 40.8† 42.8† 11.2
Social 
Functioning
Mean 
score 
(SD)
64.8 (25.2) 64.0 (24.4) 50.6 (25.1) 66.6 (25.7) 65.7 (24.4) 50.8 (25.7) 67.2 (25.9) 66.2 (25.3) 50.6 (25.4)
Mean 
change 
from BL
15.6 (1.6)† 14.7 (1.6)† 2.6 (1.9) 18.3 (1.3)† 18.1 (1.3)† 3.4 (1.8) 18.5 (1.3)† 18.6 (1.3)† 3.2 (1.8)
% MCID 39.5‡ 36.8 30.1 45.3† 48.3† 11.7 43.5† 44.4† 11.2
Role 
Emotional
Mean 
score 
(SD)
50.4 (43.0) 50.8 (43.9) 37.4 (41.2) 50.2 (42.9) 54.1 (43.4) 36.3 (40.9) 52.8 (43.0) 53.9 (43.5) 35.7 (40.6)
Mean 
change 
from BL
19.2 (2.8)‡ 19.3 (2.9)‡ 6.6 (3.3) 22.2 (2.2)† 26.4 (2.2)† 7.8 (3.1) 23.9 (2.3)† 26.1 (2.2)† 7.1 (3.1)
% MCID 25.5‡ 22.4 17.4 31.7† 33.2† 10.8 29.0† 29.7† 9.2
Mental 
Health
Mean 
score 
(SD)
64.1 (19.4) 64.5 (20.2) 56.1 (19.7) 64.3 (20.1) 63.8 (20.2) 56.3 (21.1) 64.3 (20.4) 63.3 (19.9) 55.8 (21.1)
Mean 
change 
from BL
9.3 (1.2)† 8.9 (1.2)† 2.1 (1.4) 11.0 (1.0)† 10.5 (1.0)† 3.7 (1.3) 10.7 (1.0)† 9.9 (1.0)† 3.0 (1.4)
% MCID 33.3‡ 27.4 27.0 40.8† 37.1† 14.3 37.3† 33.9† 11.2
*SF-36 PCS, MCS and domain scores, adjusted mean change from baseline, and percentage of patients reporting improvements meeting or 
exceeding MCID. Changes from baseline were analyzed using ANCOVA with region and treatment as factors, and baseline as covariate (using 
LOCF imputation of missing data).
†P < 0.001; ‡P < 0.05.
BL = baseline; CZP = certolizumab pegol; ITT = intent to treat; LOCF = last observation carried forward; MCID = minimal clinically important 
difference; MCS = mental component summary; MTX = methotrexate; PBO = placebo; PCS = physical component summary; SD = standard 
deviation; SF-36 = short-form 36-item health survey.
Table 2 (Continued)
Improvements in health-related quality of life at weeks 12, 24 and 52 (ITT population, LOCF)*Arthritis Research & Therapy    Vol 11 No 6    Strand et al.
Page 6 of 12
(page number not for citation purposes)
(MCIDs) for the SF-36 domains are defined as a 5.0 or more
point increase from baseline and a 2.5 or more point increase
from baseline for PCS and MCS scores [23]. Baseline SF-36
domain scores were compared with US population norms
adjusted for the age and gender distribution of the trial popu-
lation.
Fatigue (weariness, tiredness) over the past week was evalu-
ated using the Fatigue Assessment Scale (FAS), a numeric
rating scale (NRS) from 0 to 10 with higher scores indicating
greater fatigue [24]. The MCID for the FAS is 10% of the scale
range, corresponding to a one-point change [25]. Physical
function was assessed by the Health Assessment Question-
naire-Disability Index (HAQ-DI), evaluating eight activities of
daily living [26,27]. HAQ-DI scores range from 0 to 3, with
higher scores indicating lower levels of physical functioning.
Improvements of 0.22 or more points from baseline represent
the HAQ-DI MCID [28]. Patient's arthritis pain and patient's
global assessment of disease activity (PtGA) were evaluated
using 0 to 100 mm visual analog scales (VAS), where higher
scores indicate greater pain and disease activity. MCIDs for
both pain VAS and PtGA are defined as 10 mm improvements
from baseline [25,28-30].
The SF-36 was completed at baseline, week 12 and every 12
weeks thereafter until week 52 or withdrawal. All other patient-
reported outcomes were assessed at baseline, weeks 1 and 2
and every 2 weeks until week 20, followed by every 4 weeks
until week 52 or early withdrawal. Fatigue (FAS) was addition-
ally assessed at weeks 5 and 9.
Statistical analyses
Analyses were conducted on the intent-to-treat (ITT) popula-
tion, which included all randomized patients receiving at least
1 dose of study treatment. Changes from baseline in PRO
scores were analyzed using Analysis of Covariance
(ANCOVA) with region and treatment as factors, and baseline
score as covariate (using last observation carried forward
(LOCF) imputation of missing data). Sensitivity analyses were
performed using the repeated measures direct likelihood
method. The proportions of patients reporting improvements
equal to or greater than the determined MCID for each PRO
(post hoc analyses) were compared using repeated-measures
logistic regression with region, treatment, time and treatment
by time interaction as factors and baseline score as covariate.
Response rates (i.e., proportions of patients with clinically
meaningful improvements) in pain VAS, HAQ-DI, fatigue NRS,
and SF-36 PCS and MCS were compared at week 52 to clin-
ical response rates, defined as a decrease from baseline in
DAS28 of 1.2 units or an ACR20 response, by cross tabula-
tion. For analysis of response rates, patients with missing data
after rescue medication intake or withdrawal were imputed
with a conservative approach of non-responders.
Results
Patients
A total of 982 patients were randomized in RAPID 1: 393 to
CZP 200 mg plus MTX, 390 to CZP 400 mg plus MTX, and
199 to PBO plus MTX. Of these, 255 (64.9%), 274 (70.3%)
and 43 (21.6%) completed 52 weeks of treatment, respec-
tively [28]. At baseline, 82% of patients were female, with
mean age 52 years, 77% rheumatoid factor positive, mean dis-
ease duration 6.2 years, and having failed a mean of 1.4 dis-
ease-modifying antirheumatic drugs (DMARDs; excluding
MTX). The burden of RA at baseline was significant, as evi-
denced by patient-reported global assessment of disease
activity, pain, physical function, and fatigue scores (Table 1). In
particular, SF-36 domain scores at baseline were markedly
lower than age- and gender-matched US population norms,
and SF-36 MCS and PCS scores reflected a significant psy-
chological burden as well as physical impairments.
Figure 2
Spydergram of SF-36 domains at baseline and weeks 12 and 52 (ITT  population, LOCF) Spydergram of SF-36 domains at baseline and weeks 12 and 52 (ITT 
population, LOCF). Physical domains: Physical Function (PF), Role 
Physical (RP), Bodily Pain (BP), General Health (GH). Mental domains: 
Vitality (VT), Social Function (SF), Role Emotional (RE), Mental Health 
(MH). Domain scores are plotted from 0 (worst) at the center to 100 
(best) at the outside; demarcations along axes of the domains present 
changes of 10 points, representing 1 - 2 times MCID. As the RAPID 1 
protocol included RA subjects recruited outside North America, availa-
ble US normative data offer a 'benchmark', but less realistic goal for 
therapy. Changes from baseline for all SF-36 domains were statistically 
significant for CZP versus PBO at Weeks 12 and 52; P < 0.05. CZP = 
certolizumab pegol; ITT = intent to treat; LOCF = last observation car-
ried forward; MCID = minimal clinically important difference; PBO = 
placebo; RA = rheumatoid arthritis; RAPID 1 = RA PreventIon of Struc-
tural Damage 1; SF-36 = short-form 36-item health survey.Available online http://arthritis-research.com/content/11/6/R170
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Health-related quality of life and fatigue
RA patients receiving CZP plus MTX reported statistically sig-
nificant improvements in HRQoL compared with PBO plus
MTX by the first post-baseline assessment (week 12; P <
0.001); improvements in all eight SF-36 domains (Table 2),
PCS (Figure 1a), and MCS (Figure 1b) were sustained to
week 52. In particular, mean changes from baseline at week
12 for the CZP 200 mg plus MTX, CZP 400 mg plus MTX, and
PBO plus MTX groups were 5.6, 5.5 and 2.0 for the SF-36
MCS, respectively (Table 2; P < 0.001). Significantly more
patients treated with CZP plus MTX than PBO plus MTX also
reported improvements in SF-36 MCS equal to or greater than
the MCID from weeks 12 to 52 (Table 2; P < 0.05).
Figure 2 shows the SF-36 domain scores for the CZP 200 mg
and PBO groups compared with normative values from an
age/gender-matched US population. Baseline domain scores
reflect the largest decrements in the Role Emotional mental
domain, and the physical domains of Role Physical and Physi-
cal Function (Figure 2). Improvements exceeding MCID were
evident in all domains at week 12 and were sustained through
week 52, with the Mental Health and Vitality domains
approaching US population normative values.
Statistically significant and clinically meaningful reductions in
fatigue were reported by more patients treated with CZP plus
MTX than PBO plus MTX throughout the study (P < 0.001;
Figure 3a). At week 1, mean changes from baseline in FAS
were -1.3 and -1.2 for CZP 200 mg and 400 mg plus MTX,
respectively, compared with -0.5 for the PBO plus MTX group
(P < 0.001), and by the end of the study (week 52), mean
changes from baseline were -2.6, -2.5 and -0.8, respectively
(P < 0.001). Statistically more CZP plus MTX patients also
reported reductions in fatigue equal to or greater than the
MCID compared with PBO plus MTX (P < 0.001; Figure 4a).
At week 52, 48.9% and 48.6% of CZP 200 mg- and 400 mg-
treated patients reported fatigue reductions equal to or
Figure 3
Improvements in fatigue (a), physical function (b), pain (c) and disease activity (d) over 52 weeks (ITT population, LOCF) Improvements in fatigue (a), physical function (b), pain (c) and disease activity (d) over 52 weeks (ITT population, LOCF). *P < 0.001 for CZP vs 
PBO by ANCOVA (LOCF imputation). ANCOVA = analysis of covariance; CZP = certolizumab pegol; FAS = fatigue assessment scale; HAQ-DI = 
health assessment questionnaire - disability index; ITT = intent to treat; LOCF = last observation carried forward; MCID = minimal clinically important 
difference; MTX = methotrexate; PBO = placebo; PtGA = patient's global assessment of disease activity; VAS = visual analog scale.Arthritis Research & Therapy    Vol 11 No 6    Strand et al.
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greater than the MCID compared with only 12.6% of PBO-
treated patients (P < 0.001).
Patient-reported physical function, pain and global 
assessment of disease activity
Rapid, statistically significant improvements in physical func-
tion, as assessed by HAQ-DI, were reported by patients
treated with CZP plus MTX compared with PBO plus MTX
(Figure 3b; P < 0.001). By the end of the study at week 52,
mean scores were 1.1 for both CZP plus MTX treatment
groups, respectively, compared with baseline scores of 1.7.
Significantly more CZP plus MTX-treated patients than PBO
plus MTX-treated patients reported HAQ-DI improvements
equal to or greater than the MCID throughout the trial (P <
0.001). CZP-treated patients also reported statistically signifi-
cant improvements in physical function that met or exceeded
MCID as reported above for SF-36 PCS (Figure 1a) and Phys-
ical Functioning domain scores (Table 2).
CZP-treated patients reported significant improvements from
baseline in pain VAS (Figure 3c) and patient's global assess-
ment of disease activity (Figure 3d; P < 0.001), evident at
week 1 and sustained through week 52. Significantly more
CZP plus MTX-treated patients than PBO plus MTX-treated
patients also reported clinically meaningful reductions in pain
(Figure 4c) and improvements in global assessment of disease
activity (Figure 4d) throughout the trial (P < 0.001). Results
were similar regardless of CZP dose (200 mg or 400 mg).
Sensitivity analyses showed that improvements in all PROs
were consistent with the LOCF results.
Comparison of patient-reported outcomes with DAS28 
and ACR20 response rates
To explore the relation between the patient-reported out-
comes and the physician-reported assessments of disease,
PRO responses (as defined by improvements in physical func-
tion, pain, fatigue and SF-36 scores equal to or greater than
the MCIDs) were compared with DAS28 responses (defined
Figure 4
Patients (%) achieving minimum clinically important differences in fatigue (a), physical function (b), pain (c), and disease activity (d) over 52 weeks  (ITT population, LOCF) Patients (%) achieving minimum clinically important differences in fatigue (a), physical function (b), pain (c), and disease activity (d) over 52 weeks 
(ITT population, LOCF). *P < 0.001 for CZP vs PBO by repeated measures logistic regression. CZP = certolizumab pegol; FAS = fatigue assess-
ment scale; HAQ-DI = health assessment questionnaire - disability index; ITT = intent to treat; LOCF = last observation carried forward; MCID = 
minimal clinically important difference; MTX = methotrexate; PBO = placebo; PtGA = patient's global assessment of disease activity; VAS = visual 
analog scale.Available online http://arthritis-research.com/content/11/6/R170
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as a decrease from baseline of ≥ 1.2) and ACR20 response
rates at week 52. In general, PRO responses were in agree-
ment with clinical responses as determined by either improve-
ments in RA signs and symptoms (ACR20 response rates) or
decrease in disease activity (DAS28 scores; Table 3). As
expected, classification of response according to physical
function and pain was highly correlated with ACR20 response
rates, with 88.8% and 93.6% of patients treated with CZP
200 mg plus MTX being classified the same by physical func-
tion/ACR20 and pain/ACR20, respectively. Correlations
between fatigue and ACR20 responses were also high
(90.0%) as were those between patient's global assessment
of disease activity (98.0%), while changes in HRQoL (SF-36
PCS and MCS scores) had the lowest correlation with ACR20
responses (84.3% and 77.4%, respectively).
Results were similar for correlations between PRO responses
and DAS28 responses, with SF-36 PCS and MCS scores
showing the lowest correlations with DAS28 responses
(82.4% and 77.6%, respectively) and physical function,
fatigue, pain and global assessment of disease activity show-
ing the highest correlations (88.0%, 90.6%, 92.8% and
93.6%, respectively).
Discussion
Over the past decade, the management of RA has changed
dramatically as a result of the development of the TNF inhibi-
tors, which have resulted in improved long-term outcomes. Ini-
tially, improved clinical responses achieved by the use of TNF
inhibitors were the primary focus of clinicians. Now the RA bur-
den as reported by patients has come to be recognized as a
significant and treatable component of the disease. Utilized
together, clinical and patient-reported outcomes reflect the
spectrum of patients' disease and best reflect the overall
effectiveness of TNF inhibitor therapy in RA.
Concepts that have traditionally been shown to be among the
most important to RA patients are physical function, pain, and
tiredness (fatigue). However, it is now well-documented that
mental health disturbance is an important consequence of RA
and a central component of the assessment of HRQoL. There-
fore in RAPID 1, the concepts that were assessed as reported
by the patients were HRQoL (including emotional, social and
physical components), fatigue, physical function, arthritis pain,
and global assessment of disease activity.
Table 3
PRO response by clinical response* at week 52 (CZP 200 mg plus MTX group, ITT population)
ACR20 response by (%)
SF-36 PCS SF-36 MCS HAQ-DI Pain FAS PtGA
Clinical 
response
No Yes No Yes No Yes No Yes No Yes No Yes
PRO 
response
No 45.5 14.7 43.4 19.5 44.4 8.7 44.4 3.8 44.1 7.1 86.9 2.0
Yes 1.0 38.8 3.1 33.9 2.6 44.4 1.0 38.2 2.8 45.9 0 11.1
Tetrachoric 
correlation 
(ASE)
0.9450 (0.0178) 0.8389 (0.0356) 0.9504 (0.0152) 0.9804 (0.0076) 0.9574 (0.0135) 0.9996 (0.0053)
DAS response by (%)
SF-36 PCS SF-36 MCS HAQ-DI Pain FAS PtGA
Clinical 
response
No Yes No Yes No Yes No Yes No Yes No Yes
PRO 
response
No 44.2 16.5 43.2 20.4 43.6 10.0 43.6 5.1 43.9 7.7 44.1 4.9
Yes 1.0 38.2 2.1 34.4 2.1 44.4 2.1 49.2 1.8 46.7 1.5 49.5
Tetrachoric 
correlation 
(ASE)
0.9344 (0.0204) 0.8674 (0.0322) 0.9496 (0.0156) 0.9776 (0.0085) 0.9672 (0.0114) 0.9833 (0.0069)
*Clinical response = DAS or ACR20 response.
ACR20 = American College of Rheumatology 20% improvement; ASE = asymptomatic standard error; CZP = certolizumab pegol; DAS = 
disease activity score; FAS = fatigue assessment scale; HAQ-DI = health assessment questionnaire-disability index; ITT = intent to treat; MCS = 
mental component summary; MTX = methotrexate; PtGA = patient's global assessment; PCS = physical component summary; PRO = patient-
reported outcomes; SF-36 = short-form 36-item health surveyArthritis Research & Therapy    Vol 11 No 6    Strand et al.
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Patients in this trial (RAPID 1) had substantially diminished
HRQoL at baseline compared with age- and gender-matched
US population norms (particularly in Vitality, Role Emotional,
Physical Function, Role Physical and Bodily Pain), as illus-
trated by the spydergram of SF-36 scores at baseline (Figure
2). The US population norms were used only as a benchmark
to allow comparisons between RA patients with available gen-
eral population data. Following treatment with either dose of
CZP plus MTX, patients reported improvements in HRQoL, or
'multidimensional function', at first assessment (week 12), with
large improvements in both the physical and mental domains
of HRQoL that exceeded MCID. In particular, energy (Vitality)
and emotional state (mental health) domain scores
approached normative values of the general population in the
US, and the significant improvement in SF-36 MCS scores
observed with CZP plus MTX treatment in this trial, which
approached levels of improvement in PCS scores, is novel
among studies of TNF inhibitors in RA [31-35]. The negative
psychological effects of RA are well documented; many
patients with RA have mood and anxiety disorders [36], and it
has been reported that 21% to 39% of patients with RA expe-
rience significant depressive symptoms [37,38], although
treatment of these aspects of the disease is often suboptimal.
The improvements in SF-36 MCS and mental health scores
following CZP treatment are thus particularly relevant for
patients because they may help them return to normal levels of
emotional functioning.
Patients treated with CZP plus MTX also reported significant
improvements in global assessment of disease activity and
physical function, as well as relief of pain and fatigue, as early
as week 1 of treatment. Although there was a small decrease
in the percentage of patients reporting clinically meaningful
reductions in fatigue from week 4 to week 52, this is likely
because of protocol-mandated withdrawal at week 16 for fail-
ure to achieve ACR20 responses at weeks 12 and/or 14, as
well as imputation of withdrawn subjects with the conservative
approach of non-responders after week 16. Reductions in
fatigue and all other PROs with CZP plus MTX remained
highly significant throughout the trial, with approximately 50%
of patients reporting clinically meaningful reductions by week
52. In general, the effect of CZP on the patient-reported out-
comes described herein are comparable with those reported
with other TNF inhibitors in clinical studies [31-35,39] as well
as in studies in clinical practice [19,32,34,40-43]. However,
the rapid improvements in patient-reported outcomes in CZP-
treated patients, particularly those reflecting improved mental
health, which have not previously been observed, are a partic-
ularly interesting characteristic of this new anti-TNF.
Patient's daily burden of disease and their poor HRQoL
directly limit their everyday activities as well as productivity at
work and within the home with negative consequences for
society. Results from the RAPID 1 trial have demonstrated that
CZP treatment improves productivity at work and at home,
including fewer number of days lost engaging in family, social
and leisure activities [44]. Furthermore, a post hoc analysis
demonstrated that these improvements in productivity were
closely reflected by similar changes in pain, physical function
and fatigue (unpublished observations).
The data presented in this paper demonstrate that the CZP-
treated patients experience early improvements in all patient-
reported outcomes over PBO. In addition, there have been
data suggesting that rapid improvements in disease activity
are associated with better long-term outcomes [45]. Patients
have a greater chance of avoiding long-term disability, allowing
them to regain their normal levels of physical, emotional and
social participation and greatly improving overall HRQoL.
Previously reported results from the RAPID 1 trial have dem-
onstrated that treatment with CZP plus MTX rapidly and signif-
icantly reduces disease activity (as assessed by DAS28
scores) and improves the clinical signs and symptoms of RA
(as assessed by ACR20 response rates) [15]. The improve-
ments in patient-reported outcomes following CZP treatment
reported herein thus support and complement these previ-
ously reported clinical improvements. In addition, the analyses
correlating responses as assessed by improvements in PROs
with clinical (ACR and DAS) responses demonstrate that
patient-reported outcomes correlate well with physician-
reported, clinical indices. Not surprisingly, because the HAQ-
DI and pain are components of the ACR20 response rate cri-
teria, physical function and pain were highly correlated with
ACR20 response rates. In contrast, changes in SF-36 PCS
and MCS scores had the lowest correlation with ACR20 and
DAS responses. These results illustrated that although clinical
measures and PROs are generally well correlated, assess-
ment of only clinical measures does not capture all aspects of
RA and its impact on patients' physical and mental health.
Assessment of both clinical (physician-reported) and patient-
reported outcomes is thus necessary to fully elucidate treat-
ment benefit.
Conclusions
The patient-reported assessments implemented in the RAPID
1 clinical trial demonstrated that RA patients experience rapid
and sustained improvements in HRQoL, fatigue, physical func-
tion, disease activity and arthritis pain. These improvements
were statistically significant and clinically meaningful from the
first post-baseline assessment through to the end of the study
period at one year. These results demonstrate that the benefits
of CZP extend beyond clinical efficacy endpoints into areas
that are more relevant and meaningful for patients on a daily
basis.
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